Oceanix Biotechnology Corporation Grand Opening

On August 13, Oceanix Biotechnology Corporation grandly opened in Delta City, BC. Carla Qualtrough, Minister of Employment, Workforce Development and Disability Placement of Canada, and Mahmoud S. Aziz, President and CEO of Canadian Oceanix Biotechnology Corporation, cut the ribbon for the company's opening.

The second from left in the picture above is Minister Qualtrough, and the third from left is President Aziz.

Oceanix Biotechnology Corp. is a leading, innovative Canadian biotechnology and biopharmaceutical company that actively participates in the global marine biotechnology and biopharmaceutical industry, and is the world’s largest producer of sustainable keyhole limpet hemocyanin (KLH) and KLH proteins. It is also the only manufacturer in Canada for the global anti-cancer vaccine and immunotherapy industries.

Minister Qualtrough congratulated the company for its official opening. She highly praised the company for overcoming many difficulties, especially during the period of the epidemic of Covid-19, all employees did not stop working, and made positive contributions to promoting Canadian economic development and increasing employment opportunities.

President Aziz said that Oceanix was founded in 2015. After six years of preparation, the company finally officially opened today. The company is not only doing business in Canada, but also in China and the Philippines, actively participating in the exploration of the ocean and marine environment, looking for new sources and supplies of marine and marine biomass, looking for potential biopharmaceuticals and pharmaceutical compounds, and also engaged in the potential of marine organisms. Continuous aquaculture, and the use of ecologically stable and sustainable marine and marine biological resources (biomass) to develop and commercialize new drugs, biological drugs, nutritional foods and OTC products. The company explores the diversity of Canadian and global marine ecosystems, develops and markets new biomedical, nutritional and food products and technologies that can only be obtained from the unique forms, structures, physiology and chemistry found in marine organisms. The company's main goal is to create high-value-added industries in Canada, China and other countries, using sustainable local marine biomass to develop consistent production, extraction, purification and commercialization processes for new molecules/bioactive compounds.

In the interview, President Aziz said that he had worked in Beijing, Shenzhen, Xi'an and other cities in China, and had a deep understanding of China. Therefore, the company will not only build a factory in Nanjing, but also build a factory in Xiamen. The scale will be much larger than the factory in Canada. President Aziz is also the President and CEO of Canada-owned Canagen Pharmaceuticals Inc., and Oceanix that opened today is a subsidiary of Canagen. Canagen is a mature and innovative multinational pharmaceutical company, actively engaged in the production and research, development and commercialization of finished drugs, generic drugs, active pharmaceutical ingredients (API) and OTC products, covering cardiovascular, tumor, dementia and anti-inflammatory drugs. New drugs in the field of virus therapy. Canagen’s Nutritional Food Division is actively involved in the research, development and commercialization of innovative nutritious foods, using best pharmaceutical practices. At the same time, Canagen owns and operates ten certified GMP pharmaceutical factories in Canada, China, India and Russia, and has specialized R&D facilities in Canada, India and China.